Using p63 and P501S to Tell Urothelial Carcinoma from Prostate Carcinoma
Author Information
Author(s): Srinivasan Malini, Parwani Anil V
Primary Institution: University of Pittsburgh Medical Center
Hypothesis
Can p63 and P501S dual immunohistochemical staining effectively differentiate between urothelial carcinoma and prostate carcinoma?
Conclusion
Double sequential immunohistochemical staining with p63 and P501S is highly specific and useful for distinguishing urothelial carcinoma from prostate carcinoma.
Supporting Evidence
- p63 was positive in 90.2% of urothelial carcinoma cases and negative in prostate carcinoma.
- P501S was positive in 95.7% of prostate carcinoma cases and negative in urothelial carcinoma.
- The p63+/P501S- profile had 100% specificity for urothelial carcinoma.
- The p63-/P501S+ profile had 100% specificity for prostate carcinoma.
Takeaway
This study shows that a special test can help doctors tell two types of cancer apart, even when they have very little tissue to look at.
Methodology
The study used dual-color sequential immunohistochemical staining on tissue samples from patients with high-grade urothelial carcinoma and prostate carcinoma.
Limitations
The study was limited to archival material and may not represent all cases of these cancers.
Participant Demographics
Patients included 132 with high-grade urothelial carcinoma and 23 with prostate carcinoma.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website